Fig. 3From: Effectiveness of NLRP3 Inhibitor as a Non-Hormonal Treatment for ovarian endometriosisEffects of MCC950 on ESCs and CSCs. (A) ESCs and CSCs were treated with MCC950 (0.01, 1, and 100 μM) and the surviving fraction was measured after a 24 h incubation. Data are shown as mean ± SEM of triplicate samples obtained from patients; ESCs (n = 4) and CSCs (n = 4). (B) Immunofluorescence analysis of the expression of NLRP3 and IL-1β in ESCs and CSCs. Representative immunostaining images (upper) and quantitative analysis (lower) of the ratio of NLRP3/IL-1β co-labeled cells to total cells after incubating with or without MCC950 (100 μM) for 16 h. Data are shown as mean ± SEM obtained from primary cell cultures; ESCs (n = 3) and CSCs (n = 3); Scale bar: 50 μm. Ratio of IL-1β (C) and IL-18 (D) levels in CSC culture supernatant from untreated and MCC950-treated (100 μM) cultures after 16 h. Data are shown as mean ± SEM of duplicates obtained from primary cell cultures; (C) ESCs (n = 7) and CSCs (n = 8), (D) ESCs (n = 7) and CSCs (n = 9). Statistical significances were calculated using one-way ANOVA followed by Dunnett’s multiple comparison test (A and B) and Student’s t-test (C and D). *P < 0.05 and **P < 0.01; ESCs eutopic endometrium-derived stromal cells, with endometriosis, CSCs ovarian endometriosis (chocolate cyst)-derived stromal cellsBack to article page